Latest United States News

Ioneer has secured non-binding letters of intent with Korea’s KIND and Hyundai Engineering, marking a key step towards a Final Investment Decision for the Rhyolite Ridge lithium-boron project, targeting first production in 2029.

Recce Pharmaceuticals has secured ethics approval to upgrade and broaden its pivotal Phase 3 trial of RECCE® 327 Topical Gel for diabetic foot infections in Australia, accelerating recruitment and reinforcing its global registration ambitions.

Andromeda Metals has started commissioning its High Purity Alumina pilot plant, aiming to produce commercial-grade 4N HPA samples in the second half of 2026 for customer qualification. The pilot plant will also explore value from by-products like amorphous silica and gallium, adding potential upside to the project.

Amaero has fast-tracked the commissioning of its third advanced atomizer, expanding its US production capacity for refractory and titanium powders. The company completes a major capital plan on budget and prepares for a potential US IPO.

Freedom Bidco has increased its unsolicited cash offer for Strata Investment Holdings to A$0.22 per share, presenting shareholders with a premium liquidity option ahead of Strata’s imminent ASX delisting. The offer includes a cash alternative and a share swap, while Freedom Bidco accuses Strata’s board of obstructive tactics and governance failings.

AML3D has completed its initial $4.5 million delivery of two ARCEMY® X systems to Newport News Shipbuilding, the largest US military shipbuilder, with a follow-up order worth $9.9 million underway for early 2027 delivery.

Vitrafy Life Sciences has launched a non-underwritten Share Purchase Plan to raise approximately A$2 million, offering existing Australian and New Zealand shareholders the chance to buy shares at A$2.60 each, matching the recent institutional placement price.

Atlas Arteria has lodged its fourth supplementary target’s statement, reiterating its rejection of IFM’s $5.10 per security takeover offer, citing undervaluation and highlighting IFM’s capacity to pay more.

Nova Minerals Corp. (ASX: NVA) has had its trading suspension lifted as of 18 June 2026, following the implementation of shareholder and warrant holder schemes of arrangement.

Actinogen Medical’s pivotal XanaMIA Alzheimer’s trial has passed a third independent safety review, endorsing continuation without changes. Final topline efficacy data is expected in November 2026.

Ragusa Minerals has completed its acquisition of a controlling interest in Pegasus Tel, gaining access to the Purple Pansy manganese-gold project in Arizona, positioning itself within a critical US supply chain sector.

Magnum Mining has mapped a substantial 3.3 km² equivalent thorium anomaly at its Wet Mountain rare earths project in Colorado, aligning with historic high-grade assays and setting the stage for initial diamond drilling.